Clozapine prescribing during follow-up of a first-episode psychosis cohort
Introduction Of those with schizophrenia, one third develop treatment-resistant illness. Nearly 60% of these benefit from clozapine- the only antipsychotic medication licensed in this group. Objectives As treatment-resistant illness developed in the follow-up of a first-episode psychosis (FEP) c...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Cambridge University Press
2021-04-01
|
| Cyfres: | European Psychiatry |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.cambridge.org/core/product/identifier/S0924933821021246/type/journal_article |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|